164 related articles for article (PubMed ID: 35085413)
21. Depletion of high-content CD14
Wang X; Borquez-Ojeda O; Stefanski J; Du F; Qu J; Chaudhari J; Thummar K; Zhu M; Shen LB; Hall M; Gautam P; Wang Y; Sénéchal B; Sikder D; Adusumilli PS; Brentjens RJ; Curran K; Geyer MB; Mailankhody S; O'Cearbhaill R; Park JH; Sauter C; Slovin S; Smith EL; Rivière I
Mol Ther Methods Clin Dev; 2021 Sep; 22():377-387. PubMed ID: 34514029
[TBL] [Abstract][Full Text] [Related]
22. Manufacturing development and clinical production of NKG2D chimeric antigen receptor-expressing T cells for autologous adoptive cell therapy.
Murad JM; Baumeister SH; Werner L; Daley H; Trébéden-Negre H; Reder J; Sentman CL; Gilham D; Lehmann F; Snykers S; Sentman ML; Wade T; Schmucker A; Fanger MW; Dranoff G; Ritz J; Nikiforow S
Cytotherapy; 2018 Jul; 20(7):952-963. PubMed ID: 30180944
[TBL] [Abstract][Full Text] [Related]
23. Establishment and validation of in-house cryopreserved CAR/TCR-T cell flow cytometry quality control.
Cai Y; Prochazkova M; Jiang C; Song HW; Jin J; Moses L; Gkitsas N; Somerville RP; Highfill SL; Panch S; Stroncek DF; Jin P
J Transl Med; 2021 Dec; 19(1):523. PubMed ID: 34952597
[TBL] [Abstract][Full Text] [Related]
24. Chimeric antigen receptor-engineered T-cell therapy for liver cancer.
Chen Y; E CY; Gong ZW; Liu S; Wang ZX; Yang YS; Zhang XW
Hepatobiliary Pancreat Dis Int; 2018 Aug; 17(4):301-309. PubMed ID: 29861325
[TBL] [Abstract][Full Text] [Related]
25. The Challenge of Variability in Chimeric Antigen Receptor T cell Manufacturing.
Fesnak AD
Regen Eng Transl Med; 2020 Sep; 6(3):322-329. PubMed ID: 33313382
[TBL] [Abstract][Full Text] [Related]
26. Optimization of manufacturing conditions for chimeric antigen receptor T cells to favor cells with a central memory phenotype.
Gargett T; Truong N; Ebert LM; Yu W; Brown MP
Cytotherapy; 2019 Jun; 21(6):593-602. PubMed ID: 30975603
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and safety of CD22 chimeric antigen receptor (CAR) T cell therapy in patients with B cell malignancies: a protocol for a systematic review and meta-analysis.
Adeel K; Fergusson NJ; Shorr R; Atkins H; Hay KA
Syst Rev; 2021 Jan; 10(1):35. PubMed ID: 33478595
[TBL] [Abstract][Full Text] [Related]
28. Timely Leukapheresis May Interfere with the "Fitness" of Lymphocytes Collected for CAR-T Treatment in High Risk DLBCL Patients.
Farina M; Chiarini M; Almici C; Accorsi Buttini E; Zuccalà F; Piva S; Volonghi I; Poli L; Bernardi S; Colnaghi F; Re F; Leoni A; Polverelli N; Turra A; Morello E; Galvagni A; Moratto D; Brugnoni D; Cattaneo C; Ferrari E; Bianchetti A; Malagola M; Re A; Russo D
Cancers (Basel); 2022 Oct; 14(21):. PubMed ID: 36358694
[TBL] [Abstract][Full Text] [Related]
29. Use of laboratory tests to guide initiation of autologous hematopoietic progenitor cell collection by apheresis: results from the multicenter hematopoietic progenitor cell collection by Apheresis Laboratory Trigger Survey.
Makar RS; Padmanabhan A; Kim HC; Anderson C; Sugrue MW; Linenberger M
Transfus Med Rev; 2014 Oct; 28(4):198-204. PubMed ID: 25311468
[TBL] [Abstract][Full Text] [Related]
30. Elutriated lymphocytes for manufacturing chimeric antigen receptor T cells.
Stroncek DF; Lee DW; Ren J; Sabatino M; Highfill S; Khuu H; Shah NN; Kaplan RN; Fry TJ; Mackall CL
J Transl Med; 2017 Mar; 15(1):59. PubMed ID: 28298232
[TBL] [Abstract][Full Text] [Related]
31. Health-related quality of life data collected in chimeric antigen receptor T-cell (CAR-T) therapy clinical trials.
Raymakers AJN; Regier DA; Peacock SJ; Freeman CL
J Cancer Policy; 2021 Dec; 30():100304. PubMed ID: 35559800
[TBL] [Abstract][Full Text] [Related]
32. CAR T Cells.
Tudor T; Binder ZA; O'Rourke DM
Neurosurg Clin N Am; 2021 Apr; 32(2):249-263. PubMed ID: 33781506
[TBL] [Abstract][Full Text] [Related]
33. Feasibility of leukapheresis for CAR T-cell production in heavily pre-treated pediatric patients.
Hutt D; Bielorai B; Baturov B; Z'orbinski I; Ilin N; Adam E; Itzhaki O; Besser MJ; Toren A; Jacoby E
Transfus Apher Sci; 2020 Aug; 59(4):102769. PubMed ID: 32414613
[TBL] [Abstract][Full Text] [Related]
34. New directions in chimeric antigen receptor T cell [CAR-T] therapy and related flow cytometry.
Maryamchik E; Gallagher KME; Preffer FI; Kadauke S; Maus MV
Cytometry B Clin Cytom; 2020 Jul; 98(4):299-327. PubMed ID: 32352629
[TBL] [Abstract][Full Text] [Related]
35. Challenges and Prospects of Chimeric Antigen Receptor T-cell Therapy for Metastatic Prostate Cancer.
Gorchakov AA; Kulemzin SV; Kochneva GV; Taranin AV
Eur Urol; 2020 Mar; 77(3):299-308. PubMed ID: 31471138
[TBL] [Abstract][Full Text] [Related]
36. Implications of CAR-T cell therapy on apheresis services: a Scottish perspective.
Horne GA; Laird J; Latif AL; Irvine D; Wilson M; Douglas K
J Clin Apher; 2021 Jun; 36(3):513-515. PubMed ID: 33378123
[No Abstract] [Full Text] [Related]
37. Clinical investigation of CAR T cells for solid tumors: Lessons learned and future directions.
Bagley SJ; O'Rourke DM
Pharmacol Ther; 2020 Jan; 205():107419. PubMed ID: 31629009
[TBL] [Abstract][Full Text] [Related]
38. Deterministic Lateral Displacement: The Next-Generation CAR T-Cell Processing?
Campos-González R; Skelley AM; Gandhi K; Inglis DW; Sturm JC; Civin CI; Ward T
SLAS Technol; 2018 Aug; 23(4):338-351. PubMed ID: 29361868
[TBL] [Abstract][Full Text] [Related]
39. Manufacturing Chimeric Antigen Receptor (CAR) T Cells for Adoptive Immunotherapy.
Ghassemi S; Milone MC
J Vis Exp; 2019 Dec; (154):. PubMed ID: 31904011
[TBL] [Abstract][Full Text] [Related]
40. [Not Available].
Rahal I; Cabannes-Hamy A; Boissel N
Bull Cancer; 2018 Dec; 105 Suppl 2():S158-S167. PubMed ID: 30686354
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
